Collin Brummel
Overview
Explore the profile of Collin Brummel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Haring C, Smith J, Dermody S, McHugh J, Perry W, Brummel C, et al.
Head Neck
. 2025 Mar;
PMID: 40045701
Objectives: To determine if the assessment of CD8+ tumor-infiltrating lymphocytes (TILs) adds prognostic information to the PD-L1 combined positive score (CPS) in recurrent/metastatic (R/M) head and neck squamous cell carcinoma...
2.
Gensterblum-Miller E, Bhangale A, Majid D, Pienkowski V, Rydzanicz M, Janiszewska J, et al.
Oral Oncol
. 2024 Nov;
159:107108.
PMID: 39549430
Mucoepidermoid Carcinoma (MEC) is a common salivary malignant neoplasm. Approximately 60 % of MECs harbor translocations between CRTC1 or CRTC3 and MAML2, which are thought to drive disease pathogenesis. However,...
3.
Bhambhani C, Kang Q, Hovelson D, Sandford E, Olesnavich M, Dermody S, et al.
JCI Insight
. 2024 Mar;
9(6).
PMID: 38516891
BACKGROUNDTransrenal cell-free tumor DNA (TR-ctDNA), which transits from the bloodstream into urine, has the potential to enable noninvasive cancer detection for a wide variety of nonurologic cancer types.MethodsUsing whole-genome sequencing,...
4.
Bhambhani C, Sandford E, Haring C, Brummel C, Tuck K, Olesnavich M, et al.
Oral Oncol
. 2023 Jun;
143:106436.
PMID: 37269557
Objectives: To develop a high-performance droplet digital PCR (ddPCR) assay capable of enhancing the detection of human papillomavirus (HPV) circulating tumor DNA (ctDNA) in plasma from patients with HPV-associated oropharyngeal...
5.
Haring C, Kana L, Dermody S, Brummel C, McHugh J, Casper K, et al.
Cancer
. 2023 May;
129(18):2817-2827.
PMID: 37162461
Background: Development of evidence-based post-treatment surveillance guidelines in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is limited by comprehensive documentation of patterns of recurrence and metastatic spread. Methods:...
6.
Smith J, Ludwig M, Bhangale A, Brummel C, Swiecicki P, Worden F, et al.
Head Neck
. 2023 Mar;
45(5):1281-1287.
PMID: 36932871
Background: We sought to characterize early changes in CD8 tumor-infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16-positive oropharyngeal cancer on a phase II clinical de-escalation...
7.
Gu W, Bhangale A, Heft Neal M, Smith J, Brummel C, McHugh J, et al.
Viruses
. 2022 Nov;
14(11).
PMID: 36366450
Mucoepidermoid Carcinomas (MEC) represent the most common malignancies of salivary glands. Approximately 50% of all MEC cases are known to harbor gene fusions, but the additional molecular drivers remain largely...
8.
Spector-Bagdady K, Kent M, Krenz C, Brummel C, Swiecicki P, Brenner J, et al.
JMIR Cancer
. 2022 May;
8(2):e35033.
PMID: 35503525
Background: The genomic frontier continues to revolutionize the practice of oncology. Advances in cancer biology from tumorigenesis to treatment resistance are driven by the molecular underpinnings of malignancy. The framing...
9.
Cao Y, Haring C, Brummel C, Bhambhani C, Aryal M, Lee C, et al.
Clin Cancer Res
. 2021 Oct;
28(2):350-359.
PMID: 34702772
Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC), (i) to investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and association with tumor progression after chemoradiation, and...
10.
Haring C, Bhambhani C, Brummel C, Jewell B, Bellile E, Heft Neal M, et al.
Oncotarget
. 2021 Jul;
12(13):1214-1229.
PMID: 34194620
Despite the rising incidence of human papillomavirus related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), treatment of metastatic disease remains palliative. Even with new treatments such as immunotherapy, response rates are...